首頁 > 市場調查報告書 > 製藥

疼痛

偏頭痛藥物市場規模、佔有率和成長分析（按治療方法、治療領域、給藥途徑和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1896791

偏頭痛藥物市場規模、佔有率和成長分析（按治療方法、治療領域、給藥途徑和地區分類）－2026-2033年產業預測

Migraine Drugs Market Size, Share, and Growth Analysis, By Treatment Class, By Therapeutic Class, By Route of Administration, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 207 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，偏頭痛藥物市場規模將達到 53.1 億美元，到 2025 年將成長至 62.7 億美元，到 2033 年將成長至 235.5 億美元，在預測期（2026-2033 年）內複合年成長率為 18%。

偏頭痛藥物市場主要集中在旨在緩解或預防偏頭痛症狀的藥物，並分為急性治療和預防性治療兩大類。急性藥物用於治療最近一次偏頭痛發作，而預防性治療則旨在降低嚴重發作的頻率。推動市場成長的因素包括：人們對有效預防方案的認知不斷提高、診斷能力的進步以及創新治療方法的引入。然而，新型治療方法的高成本和潛在副作用阻礙了市場成長，並可能導致醫療服務提供者和患者猶豫不決。儘管面臨這些挑戰，但由於藥物研發的進步、個人化醫療的興起以及新興市場機會的不斷擴大，預計該市場仍將實現顯著成長。

偏頭痛藥物市場促進因素

偏頭痛藥物市場的主要驅動力是CGRP拮抗劑和抑制劑等創新藥物的出現，這些藥物代表了偏頭痛治療的突破。這些新療法採用複雜的作用機制，已被證明能有效降低偏頭痛的強度和發作頻率，從而進一步推動了市場擴張。此外，對偏頭痛根本原因的持續研究也催生了更先進的治療方案。對偏頭痛遺傳和分子基礎的深入了解正在推動個人化治療的發展，為這種令人痛苦的疾病的個人化管理鋪平了道路。

限制偏頭痛藥物市場的因素

偏頭痛藥物市場面臨許多挑戰，包括患者對某些藥物的不滿意和接受度低，這主要是由於治療效果因人而異。這種差異可能導致患者尋求他們認為更有效的替代療法。此外，一些新型治療方法會產生副作用，影響患者的生活品質。因此，患者可能會被迫停止使用這些藥物，或需要服用其他藥物來控制副作用。諸如此類的問題凸顯了市場的複雜性，並強調了偏頭痛治療需要更個人化的方法。

偏頭痛治療市場趨勢

偏頭痛治療市場正經歷著向CGRP抑制劑的顯著轉變。這些藥物正迅速成為患者和醫療保健提供者的首選。諸如Aimovig、Emgality和Ajovy等創新治療方法已顯示出顯著療效，能夠降低偏頭痛發作的頻率和強度，並正被慢性偏頭痛患者廣泛接受。這些藥物的優勢在於其個人化的給藥方案，允許每月或每季給藥，從而提高患者的依從性和生活品質。隨著人們對偏頭痛嚴重影響的認知不斷提高，對CGRP抑制劑等有效預防性治療的需求預計將進一步成長。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 西班牙
- 法國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較

主要企業簡介

Pfizer
GlaxoSmithKline
Allergan
Amgen
Eli Lilly
Teva Pharma
Biohaven Pharma
Johnson & Johnson
Valeant Pharma
AbbVie Inc
Eli Lilly and Company
Novartis International AG
Novartis International AG
Biohaven Pharmaceuticals
Boehringer Ingelheim
Zynerba Pharmaceuticals
Teva Pharmaceutical
Hoffmann-La Roche Ltd
Amgen
AstraZeneca

結論與建議

簡介目錄

Product Code: SQMIG35I2350

Migraine Drugs Market size was valued at USD 5.31 Billion in 2024 and is poised to grow from USD 6.27 Billion in 2025 to USD 23.55 Billion by 2033, growing at a CAGR of 18% during the forecast period (2026-2033).

The migraine drugs market is focused on medications designed to alleviate or prevent migraine symptoms, categorized into acute and preventive treatments. Acute medications address recent migraine attacks, while preventive options aim to reduce the frequency of severe episodes. The market is propelled by heightened awareness of effective preventive solutions, advancements in diagnostic capabilities, and the introduction of innovative therapies. However, growth is hindered by the high cost of new treatments and potential side effects, which can lead to hesitancy among healthcare providers and patients. Despite these challenges, the market is poised for significant growth, driven by advancements in drug development, a shift towards personalized medicine, and expanding opportunities in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Migraine Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Migraine Drugs Market Segments Analysis

Global Migraine Drugs Market is segmented by Treatment, Therapeutic Class, Route of Administration, Age Group, Availability and region. Based on Treatment, the market is segmented into Acute, Preventive. Based on Therapeutic Class, the market is segmented into CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Others. Based on Age Group, the market is segmented into Pediatric, Adult, Geriatric. Based on Availability, the market is segmented into Prescription Drugs, Over-the-Counter (OTC) Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Migraine Drugs Market

The Migraine Drugs market is significantly driven by the emergence of innovative drug classes such as CGRP gepants and inhibitors, which symbolize substantial advancements in migraine treatment. These new therapies employ precise mechanisms that have demonstrated their effectiveness in reducing both the intensity and occurrence of migraines, further stimulating market expansion. Additionally, ongoing research into the underlying causes of migraines is leading to the creation of advanced therapeutic options. Enhancements in understanding the genetic and molecular foundations of migraines are facilitating the rise of personalized treatments, setting the stage for a more tailored approach to managing this debilitating condition.

Restraints in the Migraine Drugs Market

The Migraine Drugs market faces significant challenges, as the efficacy of various treatments can vary widely among patients, leading to dissatisfaction and decreased acceptance of certain medications. This variability may prompt individuals to seek alternative therapies that they perceive as more effective. Additionally, some new treatments are associated with side effects that can hinder patients' quality of life, causing them to either stop using these medications or rely on additional drugs to manage adverse reactions. Such issues highlight the complexities within the market and underscore the need for more personalized approaches in migraine treatment.

Market Trends of the Migraine Drugs Market

The migraine drugs market is experiencing a significant shift toward CGRP inhibitors, which have rapidly emerged as a preferred choice for both patients and healthcare providers. These innovative treatments, exemplified by products such as Aimovig, Emgality, and Ajovy, demonstrate remarkable efficacy in reducing the frequency and intensity of migraines, leading to increased acceptance among chronic sufferers. The appeal of these medications lies in their personalized dosing regimen, allowing for monthly or quarterly administration that enhances patient compliance and quality of life. As awareness of migraine's debilitating impact grows, the demand for effective preventive treatments like CGRP inhibitors is expected to flourish.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Technological Advancement
Regulatory Landscape
Patent Analysis
Value Chain Analysis
Case Study Analysis
PESTEL Analysis
Macro-Economic Indicators
Trade Analysis
Market Attractiveness Index
Supply Chain Analysis
Pricing Analysis

Global Migraine Drugs Market Size by Treatment & CAGR (2026-2033)

Acute
Preventive

Global Migraine Drugs Market Size by Therapeutic Class & CAGR (2026-2033)

CGRP monoclonal antibodies
CGRP small molecule antagonists
Acetylcholine inhibitors/ neurotoxins
Triptans
Ditans
Ergot alkaloids
NSAIDs
Others

Global Migraine Drugs Market Size by Route of Administration & CAGR (2026-2033)

Oral
Injectable
Others

Global Migraine Drugs Market Size by Age Group & CAGR (2026-2033)

Pediatric
Adult
Geriatric

Global Migraine Drugs Market Size by Availability & CAGR (2026-2033)

Prescription Drugs
Over-the-Counter (OTC) Drugs

Global Migraine Drugs Market Size & CAGR (2026-2033)

North America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- US
- Canada
Europe, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- Brazil
- Rest of Latin America
Middle East & Africa, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biohaven Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valeant Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biohaven Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zynerba Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments